Renaissance Capital logo

Ortho Clinical Diagnostics Priced, Nasdaq: OCDX

Carlyle-backed global provider of in vitro diagnostic products.

Industry: Health Care

First Day Return: -5.3%

Industry: Health Care

We are a pure-play in vitro diagnostics (“IVD”) business driven by our credo, “Because Every Test is A Life.” This guiding principle reflects the crucial role diagnostics play in global health and guides our priorities as an organization. As a leader in IVD, we impact approximately 800,000 patients every day. We are dedicated to improving outcomes for these patients and saving lives through providing innovative and reliable diagnostic testing solutions to the clinical laboratory and transfusion medicine communities. Our global infrastructure and commercial reach allow us to serve these markets with significant scale. We have an intense focus on the customer. We support our customers with high quality diagnostic instrumentation, a broad test portfolio and market leading service. Our products deliver consistently fast, accurate and reliable results that allow clinicians to make better-informed treatment decisions. Our business model generates significant recurring revenues and strong cash flow streams from ongoing sales of high margin consumables. In 2019, these consumables contributed more than 90% of our total revenue and approximately 93% of our core revenue.
more less
IPO Data
IPO File Date 01/04/2021
Offer Price $17.00
Price Range $20.00 - $23.00
Offer Shares (mm) 76.0
Deal Size ($mm) $1,292
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 01/27/2021
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $1,292
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Raritan, NJ, United States
Founded 1939
Employees at IPO 4,500
Website www.orthoclinical.com

Ortho Clinical Diagnostics (OCDX) Performance